Interview with Prof. Olivier Blin, Professor of Pharmacology, rare disease expert, and Orphan Dev coordinator
Despite remarkable progress in rare disease research, 90% of rare diseases still lack an approved treatment. This reality underscores the urgent need for continued innovation, patient advocacy, and smarter clinical trial designs.
What if eCOA could transform your next rare disease trial?
Imagine achieving higher data quality, stronger clinical relevance, and greater regulatory confidence.
Watch the webinar replay where Prof. Olivier Blin shares:
- How eCOAs can help overcome key challenges in rare disease clinical trials
- Real-world examples of robust eCOA strategies delivering tangible value.
- How these approaches have streamlined regulatory processes and improved trial outcomes.
Don’t miss this opportunity to explore innovative solutions that can elevate your research!
Register to see the webinar replay ▶️
Speakers
Prof. Olivier Blin
Professor of Pharmacology, rare disease expert, and Orphan Dev coordinator
Estelle Haenel
Chief Medical Officer @Kayentis
